Acasti Pharma Inc. Class A Stock News

FLORENCE, S.C.--(BUSINESS WIRE)-- #churchchms--Vanco, ACS Technologies (ACST), and the General Council on Finance and Administration (GCFA) are strengthening their partnership through an expanded ministry ecosystem designed to help United Methodist churches streamline administration, reinforce stewardship, deepen engagement, and support their mission. For years, Vanco has partnered with GCFA to...

PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights f...

Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028 Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028

FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission PRINCETON, N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a...

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Resubmission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Ther...

Grace ​Therapeutics said ‌on ​Thursday ​the U.S. ⁠Food ​and Drug ​Administration declined ​to ​approve its drug ‌for ⁠a rare ​type ​of ⁠stroke.

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information

PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced ...